Property

Ip: Community Trade Marks – Registration Refusal – Chance of Confusion

In Alcon Corporation v Of Office for Harmonisation within the Internal Market (OHIM) [2005], an indication was declined registration since the public was susceptible to confuse the goal with another similar mark.

In 1998, Alcon filed a credit card applicatoin for registration within the word mark TRAVATAN according of items within Class 5, particularly ophthalmic pharmaceutical formulations.

In 1999, Biofarma SA filed an opposition against registration of TRAVATAN, quarrelling there can be confusion while using the word mark TRIVASTAN, registered in Italia in 1986. This earlier trade mark made an appearance to get registered under Class 5 covering pharmaceutical, veterinary, hygiene products while some.

32841490 – man holding metallic trademark symbol. concept image for illustration of intellectual property or protection of products or services.

In compliance with Article 42 of Regulation No 40/94, Alcon requested that Biofarma furnish proof the TRIVASTAN mark been offer genuine utilized in Italia. Biofarma sent the requested documents to OHIM, demonstrating genuine use of TRIVASTAN in Italia.

In September 2001, the Opposition Division of OHIM found that use of TRIVASTAN was proven according in the pharmaceutical product within Class 5. The Opposition Division therefore declined registration of TRAVATAN because of this there’s prone to finish up confusion due to the visual and phonetic similarities relating to the marks. Alcon appealed this decision for that Third Board of Appeal who also rejected the appeal on a single grounds because the Opposition Division. Alcon then put on legal court of First Instance to annul the choice.

Alcon claimed that:-

Article 42(2) and (3) are actually infringed because Biofarma unsuccessful to submit proof of actual use as opposed to potential use of TRIVASTAN according of ophthalmic products and

there’s an breach of Article 8(1)(b) since the goods at issue weren’t sufficiently similar.

Legal Court of First Instance ruled that:-

  1. evidence printed by Biofarma proven genuine use of TRIVASTAN reaches respect in the medicinal product to handle vascular disorders within the eye, and it will be unnecessary to require proof the item actually was utilized by patients with this specific purpose
  2. possible of confusion results when the public might think the help or goods into account change from same company
  3. possible of confusion is assessed using the considered everybody within the marks and products or services into account and
  4. the twelve signs into account were visually and phonetically similar there’d do well similarity relating to the items that will create a chance of confusion.

The approval was therefore overlooked.

Comment: Make sure that the searched for trade mark won’t be mistaken for an additional mark regarding the kind of product or actual mark.